Do analysts rate RFAI or ACTU?

Actuate Therapeutics has a consensus price target of $13.67, indicating a potential upside of 1,253.14%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than RF Acquisition Corp II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RF Acquisition Corp II 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, RFAI or ACTU?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RF Acquisition Corp II N/A N/A N/A N/A N/A Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A

Is RFAI or ACTU more profitable?

RF Acquisition Corp II's return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets RF Acquisition Corp II N/A N/A N/A Actuate Therapeutics N/A -430.93% -180.86%

Does the media favor RFAI or ACTU?

In the previous week, Actuate Therapeutics had 1 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 4 mentions for Actuate Therapeutics and 3 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 1.42 beat Actuate Therapeutics' score of 0.96 indicating that RF Acquisition Corp II is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RF Acquisition Corp II 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ACTU or ALDX?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.39 N/A

Is ACTU or ALDX more profitable?

Aldeyra Therapeutics' return on equity of -53.14% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Aldeyra Therapeutics N/A -53.14% -34.94%

Does the media prefer ACTU or FBIO?

In the previous week, Fortress Biotech had 3 more articles in the media than Actuate Therapeutics. MarketBeat recorded 7 mentions for Fortress Biotech and 4 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.96 beat Fortress Biotech's score of 0.86 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortress Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRCA or ACTU?

In the previous week, Actuate Therapeutics had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Actuate Therapeutics and 2 mentions for Verrica Pharmaceuticals. Actuate Therapeutics' average media sentiment score of 0.96 beat Verrica Pharmaceuticals' score of 0.88 indicating that Actuate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ACTU or PYPD?

PolyPid is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A PolyPid N/A N/A -$34.17M -$1.91 N/A

Is ACTU or PYPD more profitable?

PolyPid's return on equity of -269.10% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% PolyPid N/A -269.10% -138.35%

Does the media favor ACTU or PYPD?

In the previous week, PolyPid had 13 more articles in the media than Actuate Therapeutics. MarketBeat recorded 17 mentions for PolyPid and 4 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.96 beat PolyPid's score of 0.65 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PolyPid 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Actuate Therapeutics (ACTU) Competitors

$1.01 +0.03 (+3.58%)

Closing price 04:00 PM Eastern

Extended Trading

$1.02 +0.01 (+1.49%)

As of 07:34 PM Eastern

Compare

ACTU vs. RFAI, ALDX, FBIO, VRCA, and PYPD

Should you buy Actuate Therapeutics stock or one of its competitors? Actuate Therapeutics's main competitors and comparable companies include RF Acquisition Corp II (RFAI), Aldeyra Therapeutics (ALDX), Fortress Biotech (FBIO), Verrica Pharmaceuticals (VRCA), and PolyPid (PYPD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Actuate Therapeutics compare to RF Acquisition Corp II?

RF Acquisition Corp II (NASDAQ:RFAI) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

RF Acquisition Corp II's return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RF Acquisition Corp II	N/A	N/A	N/A
Actuate Therapeutics	N/A	-430.93%	-180.86%

In the previous week, Actuate Therapeutics had 1 more articles in the media than RF Acquisition Corp II. MarketBeat recorded 4 mentions for Actuate Therapeutics and 3 mentions for RF Acquisition Corp II. RF Acquisition Corp II's average media sentiment score of 1.42 beat Actuate Therapeutics' score of 0.96 indicating that RF Acquisition Corp II is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RF Acquisition Corp II	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Actuate Therapeutics has a consensus price target of $13.67, indicating a potential upside of 1,253.14%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than RF Acquisition Corp II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RF Acquisition Corp II	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Actuate Therapeutics beats RF Acquisition Corp II on 4 of the 7 factors compared between the two stocks.

How does Actuate Therapeutics compare to Aldeyra Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Aldeyra Therapeutics' return on equity of -53.14% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

In the previous week, Actuate Therapeutics had 3 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Actuate Therapeutics and 1 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 1.89 beat Actuate Therapeutics' score of 0.96 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
Aldeyra Therapeutics	Very Positive

Actuate Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Actuate Therapeutics currently has a consensus price target of $13.67, indicating a potential upside of 1,253.14%. Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 252.56%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

59.7% of Aldeyra Therapeutics shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Summary

Actuate Therapeutics beats Aldeyra Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Actuate Therapeutics compare to Fortress Biotech?

Actuate Therapeutics (NASDAQ:ACTU) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

96.5% of Fortress Biotech shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Actuate Therapeutics currently has a consensus target price of $13.67, indicating a potential upside of 1,253.14%. Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 480.20%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Actuate Therapeutics is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Fortress Biotech has a net margin of 193.12% compared to Actuate Therapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 109.66% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Fortress Biotech	193.12%	109.66%	45.56%

In the previous week, Fortress Biotech had 3 more articles in the media than Actuate Therapeutics. MarketBeat recorded 7 mentions for Fortress Biotech and 4 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.96 beat Fortress Biotech's score of 0.86 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Actuate Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Fortress Biotech has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Fortress Biotech	$66.16M	1.47	$6.82M	$3.17	0.92

Summary

Fortress Biotech beats Actuate Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Actuate Therapeutics compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Verrica Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 52.9% of Verrica Pharmaceuticals shares are owned by company insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Verrica Pharmaceuticals currently has a consensus target price of $14.50, suggesting a potential upside of 191.75%. Actuate Therapeutics has a consensus target price of $13.67, suggesting a potential upside of 1,253.14%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Actuate Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Verrica Pharmaceuticals' return on equity of -360.69% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-360.69%	-67.57%
Actuate Therapeutics	N/A	-430.93%	-180.86%

In the previous week, Actuate Therapeutics had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Actuate Therapeutics and 2 mentions for Verrica Pharmaceuticals. Actuate Therapeutics' average media sentiment score of 0.96 beat Verrica Pharmaceuticals' score of 0.88 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Verrica Pharmaceuticals has higher revenue and earnings than Actuate Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.40	-$17.89M	-$1.67	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Summary

Actuate Therapeutics beats Verrica Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Actuate Therapeutics compare to PolyPid?

Actuate Therapeutics (NASDAQ:ACTU) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Actuate Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, PolyPid has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Actuate Therapeutics currently has a consensus price target of $13.67, suggesting a potential upside of 1,253.14%. PolyPid has a consensus price target of $11.33, suggesting a potential upside of 139.10%. Given Actuate Therapeutics' higher possible upside, equities research analysts clearly believe Actuate Therapeutics is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

PolyPid is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A

26.5% of PolyPid shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, PolyPid had 13 more articles in the media than Actuate Therapeutics. MarketBeat recorded 17 mentions for PolyPid and 4 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.96 beat PolyPid's score of 0.65 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PolyPid	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PolyPid's return on equity of -269.10% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
PolyPid	N/A	-269.10%	-138.35%

Summary

Actuate Therapeutics beats PolyPid on 6 of the 11 factors compared between the two stocks.

Get Actuate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACTU vs. The Competition

Export

Metric	Actuate Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.17M	$11.73B	$6.97B	$13.04B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	-1.04	781.47	269.86	25.30
Price / Sales	N/A	750.79	601.47	101.06
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	2.97	10.81	13.08	6.33
Net Income	-$22.23M	$2.77B	$3.45B	$347.70M
7 Day Performance	-8.60%	0.17%	1.12%	1.07%
1 Month Performance	-41.62%	0.35%	1.79%	1.03%
1 Year Performance	-87.71%	161.52%	67.69%	20.77%

Actuate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACTU Actuate Therapeutics	3.6516 of 5 stars	$1.01 +3.6%	$13.67 +1,253.1%	-88.6%	$24.17M	N/A	N/A	10	News Coverage Earnings Report Short Interest Decrease
RFAI RF Acquisition Corp II	1.9506 of 5 stars	$11.10 -0.1%	N/A	+4.6%	$92.62M	N/A	N/A	N/A	News Coverage Positive News Earnings Report Short Interest Decrease
ALDX Aldeyra Therapeutics	3.4492 of 5 stars	$1.54 +1.7%	$5.50 +258.3%	-73.2%	$92.61M	N/A	N/A	10
FBIO Fortress Biotech	2.6092 of 5 stars	$2.72 +4.2%	$17.00 +525.0%	+54.4%	$90.36M	$63.26M	0.86	170	News Coverage Earnings Report Gap Down
VRCA Verrica Pharmaceuticals	3.0205 of 5 stars	$5.18 -0.8%	$14.50 +179.9%	-26.3%	$88.99M	$30.32M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACTU) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actuate Therapeutics (ACTU) Competitors

ACTU vs. RFAI, ALDX, FBIO, VRCA, and PYPD

How does Actuate Therapeutics compare to RF Acquisition Corp II?

Summary

How does Actuate Therapeutics compare to Aldeyra Therapeutics?

Summary

How does Actuate Therapeutics compare to Fortress Biotech?

Summary

How does Actuate Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Actuate Therapeutics compare to PolyPid?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actuate Therapeutics (ACTU) Competitors

ACTU vs. RFAI, ALDX, FBIO, VRCA, and PYPD

How does Actuate Therapeutics compare to RF Acquisition Corp II?

Is RFAI or ACTU more profitable?

Does the media favor RFAI or ACTU?

Which has higher valuation & earnings, RFAI or ACTU?

Do analysts rate RFAI or ACTU?

Summary

How does Actuate Therapeutics compare to Aldeyra Therapeutics?

Is ACTU or ALDX more profitable?

Does the media favor ACTU or ALDX?

Which has more volatility & risk, ACTU or ALDX?

Do analysts prefer ACTU or ALDX?

Do institutionals & insiders believe in ACTU or ALDX?

Which has better earnings and valuation, ACTU or ALDX?

Summary

How does Actuate Therapeutics compare to Fortress Biotech?

Do institutionals and insiders believe in ACTU or FBIO?

Do analysts prefer ACTU or FBIO?

Is ACTU or FBIO more profitable?

Does the media prefer ACTU or FBIO?

Which has more risk and volatility, ACTU or FBIO?

Which has stronger earnings and valuation, ACTU or FBIO?

Summary

How does Actuate Therapeutics compare to Verrica Pharmaceuticals?

Which has more risk & volatility, VRCA or ACTU?

Do institutionals & insiders hold more shares of VRCA or ACTU?

Do analysts prefer VRCA or ACTU?

Is VRCA or ACTU more profitable?

Does the media refer more to VRCA or ACTU?

Which has preferable valuation and earnings, VRCA or ACTU?

Summary

How does Actuate Therapeutics compare to PolyPid?

Which has more volatility and risk, ACTU or PYPD?

Do analysts recommend ACTU or PYPD?

Which has stronger earnings and valuation, ACTU or PYPD?

Do institutionals and insiders hold more shares of ACTU or PYPD?

Does the media favor ACTU or PYPD?

Is ACTU or PYPD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools